VXRT:OTCMKTS
Vaxart Inc
0,44 USD
arrow_upward
+1,27%(+0,0055) 1 d.
12. 10., 16:00:00 GMT-4 · USD
search
Všetky symboly
| Symbol | Cena | Zmena | % zmeny |
|---|
insights_autoGenerujú sa najdôležitejšie štatistiky pre VXRT…
Otvoriť
0,43 USD
Vysoká
0,47 USD
Nízka
0,43 USD
Trh. kap.
107,92 mil.
Priem. obj.
253,26 tis.
Objem
349,88 tis.
Pomer cena/zárobky
2,70
Max. za 52 týž.
0,84 USD
Min. za 52 týž.
0,30 USD
Výnosy na akciu
0,16 USD
Beta
1,05
Akcie v obehu
242,84 mil.
Počet zamestnancov
65
Otvoriť
0,43 USD
Vysoká
0,47 USD
Nízka
0,43 USD
Trh. kap.
107,92 mil.
Priem. obj.
253,26 tis.
Objem
349,88 tis.
Pomer cena/zárobky
2,70
Max. za 52 týž.
0,84 USD
Min. za 52 týž.
0,30 USD
Výnosy na akciu
0,16 USD
Beta
1,05
Akcie v obehu
242,84 mil.
Počet zamestnancov
65
Spravodajstvo
Z internetových zdrojov a od spravodajských partnerov
Watauga Democrat
·
pred 36 minútami
XCF Global (Nasdaq:SAFX) Announces $12M+ in Gross Product Sales and Shipments of 1.4 Million Gallons of Renewable Diesel in September
24/7 Wall St.
·
pred 52 minútami
Buffett Says a Know-Nothing Investor Can Beat the Pros. $250 a Month in the S&P 500 Could Turn Into $508,000
Reuters
·
pred 43 minútami
S&P 500, Dow futures muted after big bank earnings, chip slide weighs
Profil
Vaxart, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of oral recombinant vaccines administered using temperature-stable tablets that can be stored and shipped without refrigeration, eliminating the need for needle injection. Its development programs for oral vaccine delivery include prophylactic, enteric-coated tablet vaccines for inhibiting norovirus, seasonal influenza, respiratory syncytial virus, and human papillomavirus. It was founded in 2004 by Sean Tucker. Originally incorporated as West Coast Biologicals, Inc. in California in 2004, the company later changed its name to Vaxart, Inc. in July 2007, after reincorporating in Delaware. A significant development in the company's history was the reverse merger with Aviragen Therapeutics, Inc. on February 13, 2018, which led to Vaxart becoming a wholly owned subsidiary of Aviragen. Post-merger, the company continued as Vaxart, Inc.
Vaxart's development portfolio includes a range of oral vaccines targeting infectious diseases such as norovirus, COVID-19, and seasonal influenza, as well as therapeutic vaccines like those targeting HPV. Wikipedia
Informácie o subjekte Vaxart Inc
Generálny riaditeľ-
Zamestnanci65
Dátum založeniamar 2004
Hlavné sídloSouth San Francisco, Kalifornia, Spojené štáty americké
Odvetvie-
Webvaxart.com